Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | DHFR | P00374 | 1/20 | 0.35 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CCR1 | P32246 | 1/20 | 0.31 |
| ▸ | CCR5 | P51681 | 1/20 | 0.31 |
| ▸ | CCR8 | P51685 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | METAP2 | P50579 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL890257 | 0.81 | SCN10A (0.36) | DHFRSLC2A1AURKAKDM4ELMNA | |
| SCHEMBL25723824 | 0.81 | LMNA (0.39) | DHFRSLC2A1ALDH1A1HPGDHTT | |
| SCHEMBL25723817 | 0.80 | DHFR (0.34) | DHFRSLC2A1KDM4ELMNAHSD17B10 | |
| SCHEMBL12978393 | 0.80 | DHFR (0.34) | DHFRSLC2A1KDM4ELMNAHSD17B10 | |
| SCHEMBL25723822 | 0.80 | DYRK1A (0.46) | DHFRSLC2A1ALDH1A1HTTAURKA | |
| SCHEMBL10140962 | 0.77 | SCN10A (0.38) | DHFRSLC2A1METAP2 | |
| SCHEMBL10141921 | 0.77 | PARP1 (0.34) | DHFRSLC2A1ALDH1A1 | |
| SCHEMBL25723819 | 0.77 | CYP1A2 (0.38) | CYP1A2DHFRSLC2A1ALDH1A1HPGD | |
| SCHEMBL7922369 | 0.76 | CYP1A2 (0.41) | CYP1A2USP2ALDH1A1HPGDHTT | |
| SCHEMBL29377586 | 0.76 | CYP1A2 (0.41) | CYP1A2USP2ALDH1A1HPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023114428-A1 | HETEROCYCLE DERIVATIVES FOR THE TREATMENT OF DISEASE | Vir Biotechnology, Inc. (US) | 2023-06-22 | — | — | WO | disclosed |
| US-8221737-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-07-17 | — | — | US | disclosed |
| US-20120076755-A1 | Hepatitis C Virus Inhibitors | ENANTA PHARMACEUTICALS, INC. | 2012-03-29 | — | — | US | disclosed |
| US-20110250172-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-10-13 | — | — | US | disclosed |
| US-20110189129-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-08-04 | — | — | US | disclosed |
| US-20110142798-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-06-16 | — | — | US | disclosed |
| US-20110070196-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-03-24 | — | — | US | disclosed |
| US-20110064695-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-03-17 | — | — | US | disclosed |
| US-20110008288-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-01-13 | — | — | US | disclosed |
| US-20100317568-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2010-12-16 | — | — | US | disclosed |
| US-20100316607-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2010-12-16 | — | — | US | disclosed |
| US-20100260715-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317568-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | CYP1A2 2958/4885DHFR 2089/4885SLC2A1 4099/4885 |
| US-20110250172-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | CYP1A2 205/4885DHFR 1153/4885SLC2A1 1026/4885 |
| US-20100260715-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | CYP1A2 205/4885DHFR 1153/4885SLC2A1 1026/4885 |
| US-20100316607-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | CYP1A2 205/4885DHFR 1153/4885SLC2A1 1026/4885 |
| US-20110189129-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, HCCS, NSUN2 | CYP1A2 358/4885DHFR 1964/4885SLC2A1 1364/4885 |
| US-20110142798-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | CYP1A2 205/4885DHFR 1153/4885SLC2A1 1026/4885 |
| US-20110008288-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | CYP1A2 205/4885DHFR 1153/4885SLC2A1 1026/4885 |
| US-20110070196-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, EIF2AK2, SLC10A1 | CYP1A2 205/4885DHFR 1356/4885SLC2A1 1505/4885 |
| US-20110064695-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, EIF2AK2, SLC10A1 | CYP1A2 205/4885DHFR 1356/4885SLC2A1 1505/4885 |
| US-20120076755-A1 | Hepatitis C Virus Inhibitors | NSUN2, HCCS, HAVCR2 | CYP1A2 375/4885DHFR 2044/4885SLC2A1 1401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.